A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis

Inclusion Criteria:

• Diagnosis of AD with onset of symptoms at least 1 year prior to the Baseline Visitand participant meets Hanifin and Rajka criteria.

• Participant has applied non-medicated, additive-free bland emollient twice daily forat least 7 days before the Baseline Visit.

• History of inadequate response to topical corticosteroids (TCS), topical calcineurininhibitors (TCI), or topical JAK inhibitors, OR systemic treatment for AD, ORparticipants for whom topical treatments are otherwise medically inadvisable (e.g.,because of important side effects or safety risks).

Exclusion Criteria:

• Use of the following AD treatments within the specified washout period prior to theBaseline Visit:

-- Systemic therapy for AD, including but not limited to corticosteroids,methotrexate, cyclosporine, azathioprine, phosphodiesterase type 4 (PDE4)inhibitors, IFN-γ, and mycophenolate mofetil within 5 half-lives [if known] orwithin 4 weeks, whichever is longer;

-- Any biologic treatments, (within 5 half-lives [if known]) or within 12 weeks (whichever is longer), or as specified below: < 8 weeks for dupilumab; < 12 weeksfor nemolizumab; < 16 weeks for tralokinumab and lebrikizumab.

• Phototherapy treatment, laser therapy, tanning booth, or extended sun exposure thatcould affect disease severity or interfere with disease assessments within 4 weeks.

• Herbal treatments (e.g., traditional Chinese medicines) within 4 weeks.

• Topical treatments (with the exception of non-medicated, additive-free blandemollients), including but not limited to TCS, TCIs, or topical PDE-4 inhibitorswithin 7 days.

• Topical JAK inhibitor within 14 days.

• Systemic JAK inhibitor (including but not limited to ruxolitinib, tofacitinib,baricitinib, upadacitinib, abrocitinib [PF-04965842], and filgotinib) within 5half-lives [if known] or within 14 days, whichever is longer.